Q1 2025 · 13F-HR
Bain Capital Life Sciences Investors, LLCholdings as filed
Filed 2025-05-15 · accession 0000950123-25-005465
$675.9M
Reported value
24
Positions
2025-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $219.4M | 32.5% | 10,719,110 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $102.6M | 15.2% | 1,447,267 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $51.9M | 7.67% | 3,303,381 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $48.8M | 7.22% | 983,500 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $48.8M | 7.22% | 2,689,707 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $48.8M | 7.21% | 17,600,621 | Common | SOLE |
| 83422E204 | SLDB | SOLID BIOSCIENCES INC | $29.3M | 4.33% | 7,911,669 | Common | SOLE |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $25.7M | 3.81% | 6,843,954 | Common | SOLE |
| 75340L104 | RPID | RAPID MICRO BIOSYSTEMS INC | $22.3M | 3.29% | 8,434,560 | Common | SOLE |
| 171757206 | CDTX | CIDARA THERAPEUTICS INC | $15.1M | 2.24% | 703,080 | Common | SOLE |
| 91678A107 | UPB | UPSTREAM BIO INC | $14.0M | 2.08% | 2,295,322 | Common | SOLE |
| 03589W102 | ANNX | ANNEXON INC | $10.1M | 1.50% | 5,249,069 | Common | SOLE |
| 04683R106 | AVIR | ATEA PHARMACEUTICALS INC | $7.4M | 1.10% | 2,485,638 | Common | SOLE |
| 501976104 | KYTX | KYVERNA THERAPEUTICS INC | $6.5M | 0.96% | 3,368,370 | Common | SOLE |
| 98420X103 | ASNSUSD | X4 PHARMACEUTICALS INC | $4.0M | 0.59% | 16,915,784 | Common | SOLE |
| 12674W109 | CABA | CABALETTA BIO INC | $3.8M | 0.57% | 2,760,888 | Common | SOLE |
| 87583X109 | TNGX | TANGO THERAPEUTICS INC | $3.7M | 0.55% | 2,712,008 | Common | SOLE |
| 98422T100 | — | XILIO THERAPEUTICS INC | $3.3M | 0.49% | 4,566,817 | Common | SOLE |
| 59045L106 | — | MERSANA THERAPEUTICS INC | $3.0M | 0.44% | 8,663,673 | Common | SOLE |
| 15673T100 | IPSC | CENTURY THERAPEUTICS INC | $2.6M | 0.38% | 5,410,361 | Common | SOLE |
| 12529R107 | CCCC | C4 THERAPEUTICS INC | $1.8M | 0.26% | 1,111,910 | Common | SOLE |
| 00534A102 | IVVD | INVIVYD INC | $1.1M | 0.16% | 1,799,595 | Common | SOLE |
| 63909J108 | NAUT | NAUTILUS BIOTECHNOLOGY INC | $923,354 | 0.14% | 1,072,421 | Common | SOLE |
| N62509117 | NAMSW | NEWAMSTERDAM PHARMA COMPANY | $899,000 | 0.13% | 100,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.